Sylke Poehling, PhD, is Senior Vice President, Strategy & Portfolio at Roche Pharma Research and Early Development. She leads portfolio and project management with oversight for more than 40 projects in early development. Reporting to the Head of Research and Early Development, Sylke is a key strategic member of the Portfolio Decision-Making Committees for research and early development. Since Sylke build the group in 2014, her team has established various new tools and has implemented methodologies to effectively support strategic decision-making and portfolio analytics for the research and early development portfolio. Before taking over the Strategy & Portfolio Group, Sylke led the Global Large Molecule Research Organization, a group of approx 300 scientists and associates based in Switzerland, Germany and China. Large Molecule Research is responsible for the discovery and technical development of all therapeutic antibodies and protein for Roche’s Therapeutic Areas from lead identification through to Phase 1. Sylke joined Roche in 2005 from a privately-held German Biotech company where she led Preclinical Development. Sylke holds a diploma in Biology and a PhD in molecular biology and is a member of the Association of General and Applied Microbiology.